| Hanks, Brent Allen |
Duke University
United States |
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities |
5R01CA251136-03 |
|
Marjorie Perloff, M.D. |
| Bissonnette, Bruce Marc |
University Of Chicago
United States |
CXCR4 as a target for colon cancer chemoprevention |
5R01CA240710-05 |
|
Marjorie Perloff, M.D. |
| Hanks, Brent Allen |
Duke University
United States |
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities |
5R01CA251136-03 |
|
Marjorie Perloff, M.D. |
| Bride, Colleen M Mc |
Emory University
United States |
Testing a Low Cost Population- and Theory-Based Outreach Intervention to Engage Ovarian Cancer Survivors and their Close Relatives to Consider Genetic Services |
5U01CA240581-04 |
|
Marjorie Perloff, M.D. |
| Hanks, Brent Allen |
Duke University
United States |
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities |
5R01CA251136-03 |
|
Marjorie Perloff, M.D. |
| Infante, Rodney E |
Ut Southwestern Medical Center
United States |
Identifying the Cellular and Molecular Targets of JAK/STAT-Driven Adipose Wasting to Reverse Cancer Cachexia |
5R01CA266900-02 |
PA-20-185 (Parent R01 Clinical Trial Not Allowed) |
Marjorie Perloff, M.D. |
| Hoshida, Yujin |
Ut Southwestern Medical Center
United States |
Reverse-engineering precision liver cancer chemoprevention |
3R01CA233794-05S1 |
|
Marjorie Perloff, M.D. |
| Hofseth, Lorne J |
University Of South Carolina At Columbia
United States |
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer |
3R01CA246809-05S1 |
|
Marjorie Perloff, M.D. |
| Buchanan, Adam H |
Geisinger Clinic
United States |
Feasibility and Assessment of a Cascade Traceback Screening program - FACTS |
5U01CA240747-04 |
PAR-18-616 (U01 Clinical Trial Optional) |
Marjorie Perloff, M.D. |
| Park, Youngkyu |
Cold Spring Harbor Laboratory
United States |
Preclinical Models for Cancer Therapeutic Development |
5R50CA211506-08 |
|
Marjorie Perloff, M.D. |